BPC-157 + TB-500
“Wolverine stack”
Popular recovery combination — no human trials of either component for musculoskeletal injury, or of the combination.
Not FDA-approved. Both components unapproved and WADA-prohibited. This page describes research and public discussion; it is not a recommendation to use.
Overview
This combination is widely promoted for injury recovery. See component profiles for underlying evidence, which is predominantly animal.
Blend components
Mechanism of action
Combines BPC-157's proposed angiogenic/growth-factor effects with Tβ4's actin-mediated cell migration.
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
Online / clinic protocols D Anecdotal / community Not derived from controlled human trials. Reported for transparency, not recommendation. | Varies by product | Daily to 2× weekly | 4–6 weeks | Subcutaneous |
Clinical trials & studies
No studies of this specific combination have been published.
Safety
Side effects
- Combined unknowns of components
Contraindications
- Cancer history
- Pregnancy
- Competitive sport
Interactions
- Unknown
Long-term safety
Unknown.
Regulatory status
Unapproved / research
Both components unapproved and WADA-prohibited.
FAQ
Commonly discussed alongside
Listing a combination does not mean it has been studied or is safe.